ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$0.98
−1.35%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.30
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.40
- EPS estimate
- -$0.45
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -19.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $12
- PT range
- $7.00 – $17
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.45 | -$0.40 | Beat 11.76% | — |
| May 15, 2026 | -$0.40 | -$0.63 | Miss -59.49% | — |
| Mar 16, 2026 | -$0.31 | -$0.39 | Miss -26.46% | — |
| Nov 12, 2025 | -$0.36 | -$0.37 | Miss -2.78% | — |
| Aug 12, 2025 | -$0.36 | -$0.32 | Beat 11.11% | — |
| Mar 21, 2025 | -$0.38 | -$0.43 | Miss -13.16% | — |
| Nov 8, 2024 | -$0.53 | -$0.97 | Miss -83.02% | — |
| Aug 14, 2024 | -$0.63 | -$0.44 | Beat 30.16% | — |
| Mar 29, 2024 | -$1.35 | -$1.09 | Beat 19.26% | — |
| Aug 15, 2023 | -$1.14 | -$1.07 | Beat 6.14% | — |
| May 11, 2023 | -$0.85 | -$1.19 | Miss -40.00% | — |
| May 4, 2022 | -$0.58 | -$0.72 | Miss -24.14% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026